Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA grants orphan drug status to Amira Pharma IPF drug
Amira Pharma is now concluding Phase 1 studies with AM152, a lysophosphatidic acid (LPA) receptor 1 antagonist. Further, the company is planning to execute the Phase 2 trial
Amira Pharma is now concluding Phase 1 studies with AM152, a lysophosphatidic acid (LPA) receptor 1 antagonist. Further, the company is planning to execute the Phase 2 trial
Under the contract, Oxford Nutrascience will develop a number of pharmaceutical products for Ache by utilizing its own intellectual property. Using its physician sales network around Brazil, Ache
The trial is designed to investigate the safety and efficacy of omecamtiv mecarbil in patients with left ventricular systolic dysfunction who are hospitalized for acute heart failure. In
The tie up allows more than 6,000 providers across the State of California to access CalHIPSO’s group purchasing discount and contract terms and conditions to implement athenahealth’s cloud-based
Albemarle’s net income was $106.58m for the first quarter 2011, or $1.15 per diluted share, compared to net income of $63.31, or $ per diluted share, for the
MedGenesis said GDNF has already showed disease-modifying potential in treating parkinson’s disease and now will be evaluated for epilepsy. SynapCell will provide a detailed review of the effects
Roche NimbleGen applications process customer samples for copy number variation, DNA methylation analysis, gene expression analysis, and DNA-protein interactions and chromatin structure. Ambry Genetics said it has passed
In the study, NeuroVive is evaluating the advanced CicloMulsion cremophor-free IV cyclosporine formulation in 1,000 patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction to examine cyclosporine’s
Reportedly, orlistat’s safety has been established through 100 clinical studies involving more than 30,000 patients. GSK said alli is the only FDA approved OTC weight loss product. Orlistat
The new company will remain in Amsterdam, The Netherlands, and will specialize in solid state research and pre-formulation for pharmaceutical and biotechnology companies, as well as, pharmaceutical contract